As of Oct 21
| -1.07 / -2.18%|
The 14 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 70.00, with a high estimate of 108.00 and a low estimate of 50.00. The median estimate represents a +45.89% increase from the last price of 47.98.
The current consensus among 14 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.